Major bleeding risk associated with warfarin and co-medications in the elderly population
about
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non-Valvular Atrial Fibrillation in Australia and Singapore.Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach.The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.Safety and Effectiveness of the Denali Inferior Vena Cava Filter: Intermediate Follow-Up Results.Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease.Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome.Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.Agreement among four drug information sources for the occurrence of warfarin drug interactions in Brazilian heart disease patients with a high prevalence of Trypanosoma cruzi infection.Life-threatening drug interactions: what the physician needs to know.Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.Multiobjective optimization on antiplatelet effects of three components combination by quantitative composition-activity relationship modeling and weighted-sum method.
P2860
Q38132255-7B5FBA78-D3FB-468F-9910-C6958AD07DA2Q38417110-CB34A74F-77DD-4322-86BE-DE660A0EFE88Q38714422-40453B4B-8FE1-4402-B959-0863B37DD7B0Q38758788-5E076BB0-11E8-44B6-A3FE-A45207A3E54FQ39015806-6E89D6A2-5498-4265-B2EC-0C1DF685524DQ39036774-5C8F7462-F580-4B0B-A1E4-77CA911C9E19Q39434899-3B9DE32C-BD4F-4A2E-9629-1162AC6D775CQ40420203-72A9CDE4-BAC8-43CD-9275-0EA1917EE79DQ43650765-79E14483-2C26-4A94-8145-D930B3BB61A5Q44027927-AF5944D2-1744-4E9F-AA7E-B9749389A1A3Q46091716-F2EF4D5B-83C5-4CD8-914F-3AB7700558D9Q48145727-6EFDA4ED-69F4-421E-8F06-36E7872B93ADQ50918683-195F872C-8D9D-4589-B05F-6D7D6A866EA7Q51505075-FC91EBE2-9BA7-49D8-AB87-AF27A4186B97Q51742153-E653860F-8A56-46C6-A692-90F581AEB73D
P2860
Major bleeding risk associated with warfarin and co-medications in the elderly population
description
scientific article published on 01 October 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2011
@uk
name
Major bleeding risk associated with warfarin and co-medications in the elderly population
@en
Major bleeding risk associated with warfarin and co-medications in the elderly population
@nl
type
label
Major bleeding risk associated with warfarin and co-medications in the elderly population
@en
Major bleeding risk associated with warfarin and co-medications in the elderly population
@nl
prefLabel
Major bleeding risk associated with warfarin and co-medications in the elderly population
@en
Major bleeding risk associated with warfarin and co-medications in the elderly population
@nl
P2093
P2860
P50
P356
P1476
Major bleeding risk associated with warfarin and co-medications in the elderly population
@en
P2093
Adrian Esterman
Adrian K Preiss
Andrew L Gilbert
Emmae N Ramsay
Philip Ryan
Robyn A McDermott
Sepehr Shakib
P2860
P304
P356
10.1002/PDS.2219
P577
2011-10-01T00:00:00Z